- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | Raymond James startet Coverage für Evommune mit "Strong Buy" und Kursziel von 40 $ | 2 | Investing.com Deutsch | ||
| 07.01. | Raymond James initiates Evommune stock with Strong Buy rating, $40 target | 3 | Investing.com | ||
| 06.01. | Evommune: H.C. Wainwright startet Coverage mit "Buy"-Rating wegen Urtikaria-Potenzial | 4 | Investing.com Deutsch | ||
| 11.12.25 | Evommune, Inc. GAAP EPS of -$8.07, revenue of $10M | 1 | Seeking Alpha | ||
| 11.12.25 | Evommune, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.12.25 | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.12.25 | Evommune's Skin Disorder Candidate Has 'Blockbuster Commercial Opportunity': Analyst Projects $5 Billion Peak Sales | 3 | Benzinga.com | ||
| 01.12.25 | Leerink Partners initiates coverage on Evommune stock with Outperform rating | 1 | Investing.com | ||
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | Cantor Fitzgerald initiates Evommune stock with Overweight rating | 1 | Investing.com | ||
| 01.12.25 | Evercore ISI initiates Evommune stock with Outperform rating on dermatology potential | 1 | Investing.com | ||
| 01.12.25 | Morgan Stanley startet Coverage für Evommune mit "Overweight" - Entzündungs-Pipeline als Kurstreiber | 3 | Investing.com Deutsch | ||
| 01.12.25 | Morgan Stanley initiates Evommune stock with Overweight rating on inflammation pipeline | 1 | Investing.com | ||
| 07.11.25 | Evommune, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 07.11.25 | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.25 | New York Stock Exchange: NYSE Content Advisory: Pre-Market Update + Evommune Rises in Trading Debut | 367 | PR Newswire | NEW YORK, Nov. 7, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update... ► Artikel lesen | |
| 07.11.25 | RTW Biotech notes investee Evommune's USD150 million IPO raise | 1 | Alliance News | ||
| 07.11.25 | RTW Biotech Opp. - Evommune announces $150 million IPO | - | RNS | ||
| 06.11.25 | Evommune and BillionToOne climb on trading debut | 3 | Seeking Alpha | ||
| 06.11.25 | Evommune, BillionToOne set IPO price | 4 | Seeking Alpha | ||
| 06.11.25 | New York Stock Exchange: NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading | 232 | PR Newswire | NEW YORK, Nov. 6, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update... ► Artikel lesen |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 317,25 | +6,55 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,51 | -0,12 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,14 | -3,41 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 88,64 | +4,26 % | Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why | ||
| QIAGEN | 40,990 | +0,42 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,310 | -1,09 % | ADMA Biologics, Inc. (ADMA): A Bull Case Theory | ||
| BEAM THERAPEUTICS | 31,220 | -2,59 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| ERASCA | 9,625 | +0,68 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| CG ONCOLOGY | 54,73 | +3,13 % | CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why | ||
| JANUX THERAPEUTICS | 13,760 | +0,29 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| IMMUNOME | 22,410 | -1,93 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| TANGO THERAPEUTICS | 13,010 | +11,29 % | Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data | ||
| AMYLYX PHARMACEUTICALS | 14,300 | +5,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 10,160 | -3,24 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,350 | -3,67 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen |
Das Unternehmen EVOMMUNE INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -14,82 % bei einem Aktienkurs von 16,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.